Navigation Links
Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
Date:4/15/2008

NANJING, China, April 15 /PRNewswire-FirstCall/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2008 first quarter results on Tuesday, May 6, 2008, before the market opens in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2008 first quarter results on Tuesday, May 6, at 8 a.m. EDT (Tuesday, May 6, at 8 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

United States toll-free dial-in number: +1.866.510.0712

United States dial-in number: +1.617.597.5380

China toll-free dial-in number: 10.800.130.0399

Hong Kong dial-in number: +852.3002.1672

Please ask to be connected to Simcere's Q1 2008 Earnings Call and provide the following passcode: 95590725. Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's Web site at http://www.simcere.com.

Following the earnings conference call, an archive of the call will be available by dialing:

United States toll-free dial-in number: +1.888.286.8010

United States dial-in number: +1.617.801.6888

The passcode for replay participants is: 67719578. The telephone replay also will be archived on the "Investor Relations" section of the company's Web site at http://www.simcere.com for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com.

Investor and Media Contacts:

In China:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556 6666 ext. 8818

E-mail: zhaozhigang@simcere.com

Kejia Wu

Brunswick Group

Tel: +8610 6566 4651

Email: kwu@brunswickgroup.com

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852 3512 5033

Email: jlo@brunswickgroup.com

In the United States:

Michael Guerin

Brunswick Group

Tel: +1-212-333-3810

E-mail: mguerin@brunswickgroup.com


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Acquires a 51% Stake in Boda Pharmaceutical Co., Ltd.
2. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
3. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
4. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
5. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
6. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
7. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. Nicholas Rallis and Chris ... spent 10 years as clinical instructors for the reputable Full Mouth Rehabilitation continuing ... the program, private practitioners receive cutting-edge clinical training and learn how to perform ...
(Date:5/24/2017)... ... May 24, 2017 , ... STATEMENT OPPOSING PRESIDENT DONALD TRUMP’S ... Donald Trump’s budget, “A New Foundation for American Greatness—President's Budget FY 2018,” because ... marginalizes underserved populations, undermines productivity, and destroys the social safety net needed by ...
(Date:5/24/2017)... (PRWEB) , ... May 24, ... ... affecting the female reproductive tract in which the endometrial lining of the ... causing inflammation and pain. Patients experiencing painful intercourse, painful periods, pelvic pain, ...
(Date:5/24/2017)... ... ... If you are thinking of a visit to San Francisco , fall is a ... time to visit. , Business Architecture Associates is pleased to offer 5 days of training ... 4-½ day package for individuals, and as 4-½ day corporate package for up to 3 ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 Radiology has become ... its costs have also spiraled to the number one ... to radiology than ever before as the most complete ... a patient with lower back pain an MRI may ... reason for pain, resulting in entirely different treatment protocols.  ...
(Date:5/9/2017)...  Semler Scientific, Inc. (OTCQB: SMLR), an emerging ... the clinical effectiveness and efficiency of healthcare providers, ... ended March 31, 2017. "We ... identify when preventive care options are appropriate, which ... attacks or strokes occur," said Doug Murphy-Chutorian ...
(Date:5/6/2017)...  Hill-Rom Holdings, Inc. (NYSE: HRC), has begun a ... to its Welch Allyn campus. The ... more than 100 new jobs to Central ... a significant presence for more than 100 years. Hill-Rom,s ... large portion of which will be R&D and engineering ...
Breaking Medicine Technology: